NZ502133A - Method of enhancing bioavailability of fexofenadine and its derivatives - Google Patents

Method of enhancing bioavailability of fexofenadine and its derivatives

Info

Publication number
NZ502133A
NZ502133A NZ502133A NZ50213398A NZ502133A NZ 502133 A NZ502133 A NZ 502133A NZ 502133 A NZ502133 A NZ 502133A NZ 50213398 A NZ50213398 A NZ 50213398A NZ 502133 A NZ502133 A NZ 502133A
Authority
NZ
New Zealand
Prior art keywords
fexofenadine
derivatives
enhancing bioavailability
effective
glycoprotein
Prior art date
Application number
NZ502133A
Other languages
English (en)
Inventor
Kin-Kai Hwang
Dennis H Giesing
Gail H Hurst
Original Assignee
Aventis Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aventis Pharma Inc filed Critical Aventis Pharma Inc
Publication of NZ502133A publication Critical patent/NZ502133A/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/74—Synthetic polymeric materials
    • A61K31/745—Polymers of hydrocarbons
    • A61K31/75—Polymers of hydrocarbons of ethene
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/74—Synthetic polymeric materials
    • A61K31/765—Polymers containing oxygen
    • A61K31/77—Polymers containing oxygen of oxiranes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Inorganic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Saccharide Compounds (AREA)
NZ502133A 1997-08-14 1998-07-21 Method of enhancing bioavailability of fexofenadine and its derivatives NZ502133A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US91156397A 1997-08-14 1997-08-14
PCT/US1998/015098 WO1999008690A1 (en) 1997-08-14 1998-07-21 Method of enhancing bioavailability of fexofenadine and its derivatives

Publications (1)

Publication Number Publication Date
NZ502133A true NZ502133A (en) 2002-03-28

Family

ID=25430473

Family Applications (1)

Application Number Title Priority Date Filing Date
NZ502133A NZ502133A (en) 1997-08-14 1998-07-21 Method of enhancing bioavailability of fexofenadine and its derivatives

Country Status (29)

Country Link
EP (1) EP1003528B1 (enExample)
JP (1) JP4295913B2 (enExample)
KR (1) KR100522985B1 (enExample)
CN (1) CN1143680C (enExample)
AR (1) AR018505A1 (enExample)
AT (1) ATE224721T1 (enExample)
AU (1) AU725965C (enExample)
BR (1) BR9811937A (enExample)
CA (1) CA2301267C (enExample)
CZ (1) CZ293666B6 (enExample)
DE (1) DE69808303T2 (enExample)
DK (1) DK1003528T3 (enExample)
EE (1) EE04263B1 (enExample)
ES (1) ES2179523T3 (enExample)
HU (1) HU226823B1 (enExample)
ID (1) ID24463A (enExample)
IL (1) IL134521A (enExample)
NO (1) NO325148B1 (enExample)
NZ (1) NZ502133A (enExample)
OA (1) OA11287A (enExample)
PL (1) PL191607B1 (enExample)
PT (1) PT1003528E (enExample)
RU (1) RU2197967C2 (enExample)
SK (1) SK283868B6 (enExample)
TR (1) TR200000419T2 (enExample)
TW (1) TWI240633B (enExample)
UA (1) UA64765C2 (enExample)
WO (1) WO1999008690A1 (enExample)
ZA (1) ZA987221B (enExample)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69624559T2 (de) 1995-02-28 2003-07-10 Aventis Pharmaceuticals Inc., Bridgewater Arzneizubereitungen für piperidinalkanolderivate
EP0998272B1 (en) * 1997-08-26 2003-05-02 Aventis Pharmaceuticals Inc. Pharmaceutical composition for combination of piperidinoalkanol-decongestant
GB9822170D0 (en) * 1998-10-13 1998-12-02 Danbioyst Uk Ltd Novel formulations of fexofenadine
WO2003101437A2 (en) * 2002-05-29 2003-12-11 Aventis Pharmaceuticals Holdings Inc. Method of treating asthma using fexofenadine
GB0319935D0 (en) * 2003-08-26 2003-09-24 Cipla Ltd Polymorphs
PE20060416A1 (es) * 2004-08-03 2006-06-09 Novartis Ag Composicion de inhibidores de renina e inhibidores de proteinas de efusion
JP2008120684A (ja) * 2005-03-07 2008-05-29 Kumamoto Univ 抗アレルギー薬
KR101106374B1 (ko) 2009-06-05 2012-01-19 민병욱 고체연료에 의한 가연성 가스 발생 장치
KR101117014B1 (ko) * 2009-09-09 2012-06-14 민병욱 부패성 폐기물의 바이오매스 처리에 의한 폐자원 재활용 방법 및 장치
CN101843616B (zh) * 2010-06-04 2011-07-27 西安万隆制药有限责任公司 一种盐酸非索非那定与微晶纤维素组合物及其制备方法
RU2453315C2 (ru) * 2010-08-17 2012-06-20 Открытое акционерное общество "Химико-фармацевтический комбинат "АКРИХИН" (ОАО "АКРИХИН") Фармацевтическая композиция для лечения аллергических заболеваний
EA201391742A1 (ru) 2011-05-20 2014-04-30 Авентис Фармасьютикалз Инк. Фармацевтическая композиция, включающая фексофенадин
RU2504018C1 (ru) * 2012-05-28 2014-01-10 Государственное бюджетное образовательное учреждение высшего профессионального образования "Рязанский государственный медицинский университет имени академика И.П. Павлова" Министерства здравоохранения и социального развития Российской Федерации Способ моделирования состояния индукции функциональной активности гликопротеина-р финастеридом в эксперименте
RU2553362C1 (ru) * 2014-01-09 2015-06-10 Государственное бюджетное образовательное учреждение высшего профессионального образования "Рязанский государственный медицинский университет имени академика И.П. Павлова" Министерства здравоохранения Российской Федерации Способ моделирования состояния ингибирования функциональной активности гликопротеина-р линестренолом в эксперименте
CN104188998A (zh) * 2014-09-18 2014-12-10 中山大学 一种柚皮苷与盐酸非索非那丁药物组合物及其制剂

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4254129A (en) * 1979-04-10 1981-03-03 Richardson-Merrell Inc. Piperidine derivatives
NO900427L (no) * 1989-01-31 1990-08-01 Int Pharma Agentur Erosjonsregulert frigjoeringssystem for aktive stoffer og en fremgangsmaate for deres fremstilling.
US5567592A (en) * 1994-02-02 1996-10-22 Regents Of The University Of California Screening method for the identification of bioenhancers through the inhibition of P-glycoprotein transport in the gut of a mammal
CA2224227A1 (en) * 1995-06-07 1996-12-19 Avmax, Inc. Use of essential oils to increase bioavailability of oral pharmaceutical compounds
AU5893796A (en) * 1995-06-07 1996-12-30 Novo Nordisk A/S Modification of polypeptides

Also Published As

Publication number Publication date
NO20000706L (no) 2000-04-13
CZ293666B6 (cs) 2004-06-16
EP1003528A1 (en) 2000-05-31
RU2197967C2 (ru) 2003-02-10
ZA987221B (en) 1999-02-15
DE69808303D1 (de) 2002-10-31
SK1842000A3 (en) 2000-08-14
HU226823B1 (hu) 2009-11-30
IL134521A0 (en) 2001-04-30
UA64765C2 (uk) 2004-03-15
WO1999008690A1 (en) 1999-02-25
DK1003528T3 (da) 2003-02-03
PL191607B1 (pl) 2006-06-30
CN1267221A (zh) 2000-09-20
HK1025901A1 (en) 2000-12-01
EE200000069A (et) 2000-10-16
CA2301267A1 (en) 1999-02-25
PL338579A1 (en) 2000-11-06
JP4295913B2 (ja) 2009-07-15
ATE224721T1 (de) 2002-10-15
KR100522985B1 (ko) 2005-10-21
CN1143680C (zh) 2004-03-31
SK283868B6 (sk) 2004-03-02
BR9811937A (pt) 2000-09-05
CZ2000522A3 (cs) 2000-09-13
DE69808303T2 (de) 2003-05-22
ID24463A (id) 2000-07-20
EP1003528B1 (en) 2002-09-25
AU725965B2 (en) 2000-10-26
OA11287A (en) 2003-10-22
NO20000706D0 (no) 2000-02-11
AU8505098A (en) 1999-03-08
AU725965C (en) 2004-04-22
TR200000419T2 (tr) 2000-09-21
HUP0003189A2 (en) 2001-03-28
EE04263B1 (et) 2004-04-15
KR20010022845A (ko) 2001-03-26
AR018505A1 (es) 2001-11-28
PT1003528E (pt) 2003-02-28
HUP0003189A3 (en) 2001-04-28
JP2001515041A (ja) 2001-09-18
CA2301267C (en) 2004-07-13
NO325148B1 (no) 2008-02-11
TWI240633B (en) 2005-10-01
ES2179523T3 (es) 2003-01-16
IL134521A (en) 2005-07-25

Similar Documents

Publication Publication Date Title
PL373903A1 (en) A combination of an nmda-antagonist and acetylcholine esterase inhibitors for the treatment of alzheimer's disease
IL104041A0 (en) Stabilized pharmaceutical compositions comprising an hmg-coa reductase inhibitor compound
WO2002008217A3 (en) COUMARIN DERIVATIVES USEFUL AS TNFα INHIBITORS
ZA200206243B (en) Tocopherols, Tocotrienols, other chroman and side chain derivatives and uses thereof
AU2002243230A1 (en) Piperidine/piperazine-type inhibitors of p38 kinase
AP2001002205A0 (en) Cyclopentyl-substituted glutaramide derivatives as inhibitors of neutral endopeptidase.
NO996578L (no) Urokinase-inhibitorer
PT831826E (pt) Composicao farmaceutica que inclui um inibidor de proteinase e um monoglicerideo
UY26338A1 (es) Formulaciones dispersables conteniendo inhibidores de la lipasa
NO20024201D0 (no) Substituerte 3-fenyl-5-alkoksy-1,3,4-oksdiazol-2-on og anvendelse derav for hemning av hormonsensitiv lipase
CA2301267A1 (en) Method of enhancing bioavailability of fexofenadine and its derivatives
AU6616400A (en) Hiv integrase inhibitors
WO2001056573A8 (en) Use of cox-2 inhibitors as gastroprokinetics
AU3118200A (en) Hiv integrase inhibitors
IT1307928B1 (it) Metodo di sintesi di nitrossimetilfenil esteri di derivatidell'aspirina.
GB9718903D0 (en) Method,compositions and kits for increasing the oral bioavailability of pharmaceutical agents
IL162325A0 (en) Hiv integrase inhibitor compounds and pharmaceutical compositions containing the same
EP1086091A4 (en) INTEGRASE HIV INHIBITORS
ATE359793T1 (de) 2-methyl-thieno-benzodiazepin formulierung
GB9907571D0 (en) Compounds
FR2688118B1 (fr) Nouvelles compositions fongicides a base d'inhibiteurs de la biosynthese des sterols.
MY133169A (en) Substituted heterocyclic benzocycloalkenes and the use thereof as substances having an analgesic effect
CA2119777A1 (en) An Ameliorant for Blood Lipid Metabolism
AU6271098A (en) Hiv integrase inhibitors
MY140504A (en) Statin-mmp inhibitor combinations

Legal Events

Date Code Title Description
PSEA Patent sealed
RENW Renewal (renewal fees accepted)
S38A Application for proceedings under section 38 (amendment of specification with leave of commissioner)

Free format text: BY WAY OF CORRECTION

S38C Proceedings under section 38 (amendment of specification with leave of commissioner): specification amended
RENW Renewal (renewal fees accepted)
RENW Renewal (renewal fees accepted)
RENW Renewal (renewal fees accepted)
EXPY Patent expired